Drug Development – Talk Bio

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

4 days ago talkbio0Tagged Billion Collaboration, Drug Development, Merck KGaA, milestone payments, nervous system disorder, RNA-targeting, royalties, Skyhawk, SkySTAR platform

Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

2 weeks ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

2 weeks ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

2 weeks ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development

Roche Doubles Down on Alzheimer’s with Next-Gen Amyloid-Lowering Drug Trontinemab

4 weeks ago talkbio0Tagged Alzheimer 's disease, amyloid-lowering drug, Biological Markers, Brainshuttle, Drug Development, Interventional procedure, Phase 3 Clinical Trials, Roche (company), TRONTIER, Trontinemab

Roche; Alzheimer’s disease; trontinemab; amyloid-lowering drug; Brainshuttle; Phase III trial; TRONTIER studies; drug development; biomarkers; early intervention

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

4 weeks ago talkbio0Tagged Advanced phase, biotechnology partnerships, covalent chemistry, Covalent Interaction, Drug Development, Inflammatory disorder, License, Matchpoint Therapeutics, Novartis, oral inhibitors

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships

Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps

1 month ago talkbio0Tagged Blepharitis, Clinical trial failure, Drug Development, MR-139, ophthalmic preparation, Phase 3 Clinical Trials, pimecrolimus, pipeline, strategic review, Viatris

Viatris; ophthalmic drug; Phase 3 study; blepharitis; MR-139; clinical trial failure; drug development; pimecrolimus; pipeline; strategic review

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

1 month ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

2 months ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

Eli Lilly Strikes $650M Deal with Juvena to Develop Muscle-Boosting Drugs

2 months ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, biotech collaboration, Drug Development, Drug Discovery, Eli, Eli Lilly, muscle health, Muscle-Boosting Drugs, Obesity, stem cell-secreted proteins

Eli Lilly; Juvena Therapeutics; muscle-boosting drugs; AI drug discovery; muscle health; biotech collaboration; stem cell secreted proteins; drug development; obesity management; $650 million deal